Kymera Therapeutics (KYMR) Other financing activities (2019 - 2026)
Kymera Therapeutics (KYMR) reported Other financing activities of $425000.0 for Q1 2026, up 53.43% year-over-year from $277000.0 in Q1 2025, and up 2.16% quarter-over-quarter from $416000.0 in Q4 2025.
Kymera Therapeutics (KYMR) Other financing activities (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has 8 years of Other financing activities data on file, last reported at $425000.0 in Q1 2026.
- Other financing activities for Q1 2026 came in at $425000.0, up 53.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (up 5.05% YoY), and the FY2025 annual result was $1.5 million, down 5.2% from the prior year.
- Other financing activities grew to $425000.0 in Q1 2026 per KYMR's latest filing, from $416000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $641000.0 in Q3 2024 and troughed at -$925000.0 in Q4 2023.
- A 5-year average of $276529.4 and a median of $327000.0 in 2023 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2023 and 2024: Other financing activities sank 403.28% in 2023, then jumped 131.68% in 2024.
- A 5-year view of Other financing activities shows it stood at $305000.0 in 2022, then slumped by 403.28% to -$925000.0 in 2023, then jumped by 131.68% to $293000.0 in 2024, then soared by 41.98% to $416000.0 in 2025, then climbed by 2.16% to $425000.0 in 2026.
- Business Quant data shows KYMR's Other financing activities at $425000.0 in Q1 2026, $416000.0 in Q4 2025, and $419000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Kymera Therapeutics | 8.84 Bn | 8.19 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 425,000.00 |
| Mar 31, 2026 | 425,000.00 |
| Dec 31, 2025 | 416,000.00 |
| Dec 31, 2025 | 416,000.00 |
| Sep 30, 2025 | 419,000.00 |
| Sep 30, 2025 | 419,000.00 |
| Jun 30, 2025 | 382,000.00 |
| Jun 30, 2025 | 382,000.00 |
| Mar 31, 2025 | 277,000.00 |
| Mar 31, 2025 | 277,000.00 |
| Dec 31, 2024 | 293,000.00 |
| Dec 31, 2024 | 293,000.00 |
| Sep 30, 2024 | 641,000.00 |
| Sep 30, 2024 | 641,000.00 |
| Jun 30, 2024 | 352,000.00 |
| Jun 30, 2024 | 352,000.00 |
| Mar 31, 2024 | 290,000.00 |
| Mar 31, 2024 | 290,000.00 |
| Dec 31, 2023 | -925,000.00 |
| Dec 31, 2023 | -925,000.00 |